2024
An update on the management of axial spondyloarthritis for sports medicine professionals
Danve A, Magrey M, Deodhar A. An update on the management of axial spondyloarthritis for sports medicine professionals. BMC Sports Science, Medicine And Rehabilitation 2024, 16: 211. PMID: 39375817, PMCID: PMC11460014, DOI: 10.1186/s13102-024-00998-z.Peer-Reviewed Original ResearchNonsteroidal anti-inflammatory drugsBiologic disease-modifying antirheumatic drugsMedicine practitionersImprove health-related quality of lifeSuspected axSpAHealth-related quality of lifeImprove health-related qualitySports medicine professionalsSports medicine practitionersChronic back painManagement of axial spondyloarthritisReferral of patientsDisease-modifying antirheumatic drugsCurrent treatment possibilitiesInadequately controlled diseaseQuality of lifeTargeted synthetic (ts) DMARDsFirst-line treatmentHeterogeneous clinical featuresLong-term outcomesDisease activity measuresPhysical therapyBack painChronic inflammatory diseaseMedicine professionalsIs yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?
Palacios C, Chowdhary V, Hao R, Danve A, Malinis M. Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings? PLOS ONE 2024, 19: e0306337. PMID: 38959249, PMCID: PMC11221665, DOI: 10.1371/journal.pone.0306337.Peer-Reviewed Original ResearchConceptsInterferon-gamma release assayDisease-modifying antirheumatic drugsInterferon-gamma release assay testLatent tuberculosis infectionNon-endemic settingsRheumatologic diseasesRisk factorsPositive interferon-gamma release assayLatent tuberculosis infection screeningLatent tuberculosis infection diagnosisPositive IGRA testMonths of rifampinLow-risk patientsRetrospective chart reviewTNF-alpha inhibitorsTB risk factorsTargeted LTBI screeningOutpatient rheumatology clinicDisease-modifying drugsIGRA testPatient demographicsAdult patientsChart reviewAntirheumatic drugsNon-endemic areas
2023
Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs
Baker H, Fine R, Suter F, Allore H, Hsiao B, Chowdhary V, Lavelle E, Chen P, Hintz R, Suter L, Danve A. Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs. Arthritis Care & Research 2023 PMID: 37382043, DOI: 10.1002/acr.25181.Peer-Reviewed Original ResearchBest practice advisoryHepatitis B virusAutoimmune rheumatic diseasesBPA implementationSynthetic disease-modifying antirheumatic drugsDisease-modifying antirheumatic drugsHepatitis C virus infectionHepatitis B surface antigenC virus infectionUse of biologicsB surface antigenQuality improvement initiativesElectronic health recordsEligible patientsAntirheumatic drugsRheumatic diseasesRheumatology practiceSociety guidelinesB virusPractice advisoryComputerized decision support systemVirus infectionRoutine screeningPatient screeningPatients